298 related articles for article (PubMed ID: 19223638)
1. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections.
Daikos GL; Petrikkos P; Psichogiou M; Kosmidis C; Vryonis E; Skoutelis A; Georgousi K; Tzouvelekis LS; Tassios PT; Bamia C; Petrikkos G
Antimicrob Agents Chemother; 2009 May; 53(5):1868-73. PubMed ID: 19223638
[TBL] [Abstract][Full Text] [Related]
2. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.
Psichogiou M; Tassios PT; Avlamis A; Stefanou I; Kosmidis C; Platsouka E; Paniara O; Xanthaki A; Toutouza M; Daikos GL; Tzouvelekis LS
J Antimicrob Chemother; 2008 Jan; 61(1):59-63. PubMed ID: 17999975
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.
Daikos GL; Vryonis E; Psichogiou M; Tzouvelekis LS; Liatis S; Petrikkos P; Kosmidis C; Tassios PT; Bamias G; Skoutelis A
J Antimicrob Chemother; 2010 Apr; 65(4):784-8. PubMed ID: 20106862
[TBL] [Abstract][Full Text] [Related]
5. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-β-Lactamase-1.
Dong F; Zhang Y; Yao K; Lu J; Guo L; Lyu S; Yang Y; Wang Y; Zheng H; Song W; Liu G
Microb Drug Resist; 2018 Mar; 24(2):154-160. PubMed ID: 28594635
[TBL] [Abstract][Full Text] [Related]
7. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.
Daikos GL; Tsaousi S; Tzouvelekis LS; Anyfantis I; Psichogiou M; Argyropoulou A; Stefanou I; Sypsa V; Miriagou V; Nepka M; Georgiadou S; Markogiannakis A; Goukos D; Skoutelis A
Antimicrob Agents Chemother; 2014; 58(4):2322-8. PubMed ID: 24514083
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan.
Chang YY; Chuang YC; Siu LK; Wu TL; Lin JC; Lu PL; Wang JT; Wang LS; Lin YT; Huang LJ; Fung CP
J Microbiol Immunol Infect; 2015 Apr; 48(2):219-25. PubMed ID: 25074627
[TBL] [Abstract][Full Text] [Related]
10. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
[TBL] [Abstract][Full Text] [Related]
11. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-{beta}-lactamase gene.
Ikonomidis A; Tokatlidou D; Kristo I; Sofianou D; Tsakris A; Mantzana P; Pournaras S; Maniatis AN
J Clin Microbiol; 2005 Oct; 43(10):5344-7. PubMed ID: 16208014
[TBL] [Abstract][Full Text] [Related]
12. Changing Characteristics and
Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED
Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596
[TBL] [Abstract][Full Text] [Related]
13. Recurrent healthcare-associated community-onset infections due to Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.
Poulou A; Spanakis N; Pournaras S; Pitiriga V; Ranellou K; Markou F; Tsakris A
J Antimicrob Chemother; 2010 Dec; 65(12):2538-42. PubMed ID: 20876622
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
[TBL] [Abstract][Full Text] [Related]
16. Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1.
Loli A; Tzouvelekis LS; Tzelepi E; Carattoli A; Vatopoulos AC; Tassios PT; Miriagou V
J Antimicrob Chemother; 2006 Sep; 58(3):669-72. PubMed ID: 16870645
[TBL] [Abstract][Full Text] [Related]
17. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
18. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
19. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
[TBL] [Abstract][Full Text] [Related]
20. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
